Jeremy Gleeson, MD

Articles by Jeremy Gleeson, MD

Cold Agglutinin Disease: Clinical Pearls

ByNeil Minkoff, MD,Jeremy Gleeson, MD,Jeremy Lorber, MD,Kevin U. Stephens, Sr, JD, MD ,Mihir Raval, MD, MPH

November 12th 2021

Take-aways from a discussion on the management of cold agglutinin disease, with expert insight on navigating the healthcare system to optimize patient care.

Implications for Using Complement Therapies for Cold Agglutinin Disease

ByNeil Minkoff, MD,Jeremy Lorber, MD,Mihir Raval, MD, MPH,Kevin U. Stephens, Sr, JD, MD ,Jeremy Gleeson, MD

November 12th 2021

Considerations regarding where newer, novel complement therapies will likely fit into the treatment landscape for patients with cold agglutinin disease.

Coverage for Complement Therapies for Cold Agglutinin Disease

ByNeil Minkoff, MD,Kevin U. Stephens, Sr, JD, MD ,Jeremy Gleeson, MD,Mihir Raval, MD, MPH

November 12th 2021

Payers debate criteria for coverage of novel targeted therapies under investigation as use as novel complement therapy for cold agglutinin disease.

Cold Agglutinin Disease: Treatment Gaps

ByNeil Minkoff, MD,Kevin U. Stephens, Sr, JD, MD ,Jeremy Gleeson, MD

November 5th 2021

Payers react to gaps that impact coverage decisions for therapies available off-label for cold agglutinin disease.

Coverage of Anti–B-Cell Therapies for Cold Agglutinin Disease

ByNeil Minkoff, MD,Mihir Raval, MD, MPH,Jeremy Lorber, MD,Jeremy Gleeson, MD,Kevin U. Stephens, Sr, JD, MD

October 29th 2021

Criteria that support coverage decisions for anti–B-cell therapies for cold agglutinin disease, which are not currently FDA approved.

Challenges Managing Cold Agglutinin Disease

ByNeil Minkoff, MD,Jeremy Gleeson, MD,Jeremy Lorber, MD,Mihir Raval, MD, MPH

October 15th 2021

A panel of clinicians and payers highlight challenges that impact the treatment of a rare autoimmune hemolytic anemia, cold agglutinin disease.

PRO Data & Support for Patients With Cold Agglutinin Disease

ByNeil Minkoff, MD,Kevin U. Stephens, Sr, JD, MD ,Jeremy Lorber, MD,Mihir Raval, MD, MPH,Jeremy Gleeson, MD

October 15th 2021

Payer considerations regarding the measurement of treatment outcomes for patients with cold agglutinin disease, and resources available to help support patients through their care continuum.

Cold Agglutinin Disease: Impact on Health Care Utilization

ByNeil Minkoff, MD,Mihir Raval, MD, MPH,Kevin U. Stephens, Sr, JD, MD ,Jeremy Gleeson, MD

October 1st 2021

Payers comment on main drivers of health care utilization among patients with cold agglutinin disease.

Jeremy Gleeson, MD

Articles by Jeremy Gleeson, MD

Cold Agglutinin Disease: Clinical Pearls

Implications for Using Complement Therapies for Cold Agglutinin Disease

Coverage for Complement Therapies for Cold Agglutinin Disease

Cold Agglutinin Disease: Treatment Gaps

Coverage of Anti–B-Cell Therapies for Cold Agglutinin Disease

Challenges Managing Cold Agglutinin Disease

PRO Data & Support for Patients With Cold Agglutinin Disease

Cold Agglutinin Disease: Impact on Health Care Utilization

Latest Updated Articles

Trending on AJMC

Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home

Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS

Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship

New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease

CAR T Therapy Likely the Next Frontier for Treating Patients With MG: James F. Howard, MD